Tiger Seed Hound Partners Dumps its Valeant Shares
The firm told investors it’s given up on the troubled drug maker, which has badly hurt its funds in 2016, and has embarked on a “period of introspection” over its performance.
Stephen TaubAugust 9, 2016
Jonathan Auerbach’s Hound Partners has finally thrown in the towel on Valeant Pharmaceuticals International, a stock that boosted the firm’s coffers spectacularly in recent years before tanking its portfolio over the past ten months.
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.